Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 785 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia MOST POPULAR Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective January 17, 2023 Man With Cancer Receives $15,000 Check From ‘Secret Santa’ To Help... November 16, 2021 Making a startup out of a scientist April 26, 2023 Pembrolizumab Plus Axitinib Outperforms Sunitinib in Patients with Metastatic Renal Cell... November 21, 2020 Load more HOT NEWS England slips further off-track for smokefree 2030 target ESMO Clinical Practice Guideline Express Update on the adoption of physical... FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer See How These Food Banks Are Putting Your Feed Thy Neighbor...
